Products with Antiandrogenic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5304 | Cryptotanshinone |
| Cryptotanshinone is a potent STAT3 inhibitor with IC50 of 4.6 μM, and inhibits STAT3 Tyr705 phosphorylation in DU145 prostate cancer cells. It is also an AR inhibitor to suppress androgen/AR-mediated cell growth and PSA expression by blocking AR dimerization and the AR-coregulator complex formation. Cryptotanshinone has anti-atherosclerosis, neuroprotective, anti-cancer,and anti-neointimal formation activities. Cryptotanshinone reverses DEX-induced androgen excess and ovarian IR in mice through activation of insulin signaling and the regulation of glucose transporters and hormone-synthesizing enzymes, it has an inhibitory effect on MMP-9 production and migration of human aortic smooth muscle cells treated with TNF-alpha in a dose-dependent manner. | |
| BCN5420 | Theaflavine-3,3'-digallate |
| 1. Theaflavin-3,3'-digallate is an inducer of oxidative stress and apoptosis. 2. A combination microbicide containing theaflavin-3,3'-digallate and lactic acid can reduce herpes simplex virus (HSV) transmission. 3. Theaflavin-3,3'-digallate may be useful chemoprevention agents for prostate cancer through suppressing the function of androgen and its receptor. 4. Theaflavin-3, 3'-digallate has strong antioxidant and antiangiogenic activities, it inhibits the tube formation of endothelial cells via decreased both MMP-2 and MMP-9 activities in vitro. 5. Theaflavin-3,3'-digallate may exert its anti-inflammatory and cancer chemopreventive actions by suppressing the activation of NFkappaB through inhibition of IkappaB kinase (IKK) activity. 6. Theaflavin-3,3'-digallate is a potent AMP-activated protein kinase (AMPK) activator with anti-adiposity activity in adipocytes, suggesting its potential application in functional foods and nutraceuticals for obesity management. 7. Theaflavin-3,3'-digallate can repress osteoclastogenesis and prevent wear debris-induced osteolysis via suppression of ERK pathway, it is a promising candidate for the treatment of osteoclast-related osteolytic diseases, such as wear debris-induced peri-implant osteolysis (PIO). | |
| BCN5521 | Atraric acid |
| Atraric acid derivatives as a new chemical lead structure for novel therapeutic compounds as AR antagonists, that can be used for prophylaxis or treatment of prostatic diseases. It inhibits PTP1B activity in a dose-dependent manner with IC50 values of 51.5 uM, suggest that atraric acid has potential to treat diabetes. | |
| BCN5859 | Ganoderol B |
| Ganoderol B is a potent α-glucosidase and angiotensin-converting enzyme inhibitor, with an IC(50) of α-glucosidase is 119.8 uM. It may be useful in prostate cancer and benign prostatic hyperplasia (BPH) therapy through suppressing the function of androgen and its receptor. | |
| BCN6054 | Bis(2-ethylhexyl) phthalate |
| Bis(2-ethylhexyl) phthalate (DEHP) is a compound widely used in plastics technology to impart flexibility to rigid polymers, DEHP has oral toxicity during pregnancy and suckling in the Long-Evans rat.It can induce antiandrogenic effects in Spague-Dawley (SD) rats. | |
